Stroke prevention in AF patients: SOC versus NOAC
|
|
- Tyler Allan Conley
- 8 years ago
- Views:
Transcription
1 Stroke prevention in AF patients: SOC versus NOAC Prof. Dr. Andreas Zirlik Cardio Luxor 2015 Disclosures for Andreas Zirlik, MD In compliance with CME policy, the following disclosures to the session audience are declared: Research support/p.i. Travel support Astellas, Astra Zeneca, ResMed, Novartis, Medtronic Daichi Sankyo, Astellas, Lilly, Medtronic, Pfizer, Sanofi Aventis, Novartis, Bayer Health Care Consultant Bayer, Boehringer Ingelheim, Rigel, Cardiorentis, Medscape Major stockholder Honoraria for lectures No relevant conflicts of interest to declare Bayer Health Care, Astra Zeneca, Medtronic, ResMed, Boehringer Ingelheim, Rigel, Sanofi Aventis, Pfizer, Janssen- Cilag 1
2 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Untreated atrial fibrillation bears considerable risk of stroke Death 25% Invalid 35% Pers. Deficit 35% No deficit 5% Flegel KM et al., J Clin Epidemiol
3 Placebo Warfarin ASS Warfarin ASS + Clopidogrel Warfarin 1/19/2015 Efficacy of dose-adjusted VKA Relative risk reduction thrombembolic events % % 6 5 ~30% Warfarin Warfarin Warfarin Lip et al Lip et al The ACTIVE writing group, 2006 Modified Lip GYH et al. BMJ 2002; 325: and The ACTIVE Writing Group Lancet 2006; 367: Anticoagulation with Vitamin K antagonists has many disadvantages ACC/AHA/ESC Guidelines, Eur Heart J
4 GARFIELD: OAC is underused in clinical practice Kakkar AK et al. PlosOne 2013; 8(5): e63479 New anticoagulants: Summary of pharmacology Apixaban Rivaroxaban Dabigatran Target enzyme Factor Xa Factor Xa Thrombin Bioavailability (%) Prodrug No No Yes T max (median, h) t 1/2 (h) Renal elimination (%) (in active form) 80 Adapted from Mavrakanas T, Bounameaux H. Pharmacol Ther 2011;130:
5 S T R O K E P R E V E N T I O N RE-LY: Dabigatran vs. Warfarin Pat. with AF and 1 RF, Randomization Dabigatran 2x110mg/d vs. Dabigatran 2x150mg/d vs. Warfarin, n= EP: stroke or systemic embolism Efficacy Safety Non-inferiority p=0.001 Superiority p=0.34 Non-inferiority p=0.001 Superiority p=0.001 NEJM 2009; 361: Revised Data NEJM 2010; 363:
6 RELY: Safety NEJM 2009; 361: Revised Data NEJM 2010; 363: S T R O K E P R E V E N T I O N ROCKET: Rivaroxaban vs. Warfarin Pat. with AF and 2 RF, Randomization Rivaroxaban 1x20mg/d vs. Warfarin, n= EP: stroke or systemic embolism Efficacy Safety Non-inferiority p=0.001 Superiority on per protocol analysis * * * 6
7 S T R O K E P R E V E N T I O N ARISTOTLE: Apixaban vs. Warfarin Pat. with AF and 1 RF, Randomization Apixaban 2x5mg/d vs. Warfarin, n= EP: stroke or systemic embolism Efficacy Safety Superiority p=0.001 Superiority p=0.001 Stroke or systemic embolism Major Bleeding 7
8 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach ESC Guidelines
9 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach 9
10 Case 1 A 78-year-old woman with new onset AF CVRF: coronary 2-vessel disease, acute MI two years ago, arterial hypertension Cr-Clearance around 40ml/min Otherwise good health condition On Enoxaparin s.c. therapeutically since two days Question to the audience: Does our patient need long-term therapeutic anticoagulation? 1 Yes 2 No 10
11 How to assess risk of stroke? 0 = low: no AC 1 therapeutic AC How to assess risk of bleeding? 11
12 Question to the audience: What would be your agent of choice? 1 Warfarin 2 Dabigatran 2 Rivaroxaban 3 Aspirin Case 1 A 78-year-old woman with new onset AF CVRF: coronary 2-vessel disease, acute MI two years ago, arterial hypertension Cr-Clearance around 40ml/min Otherwise good health condition On Enoxaparin s.c. therapeutically since two days 12
13 RELY: Age, renal function Safety Rate (% per year) D 110 W D 110 mg vs. W p = (for interaction) Age < 65 Age Age CrCl CrCl CrCl > 80 5,07 2,62 1,36 5,17 3,44 2,18 Healey JS et al. J Am Coll Cardiol 2010; 55: A4 Healey JS. Poster presentation at ACC, Orlando, Mar 14th 2010 Hijazi Z et al., Circulation 9 Dec 2013 Epub bevor print 0,50 1,00 1,50 Dabigatranetexilat better Warfarin better ROCKET: impaired renal function Safety 13
14 Uchino and Hernandez. Arch Int Med 2012;172:397 Meta-analysis and trial sequential analysis of RCTs: Rivaroxaban treated subjects have reduced risk for myocardial infarction Results 1 Study or Subgroup ATLAS ACS 2 TIMI 51 ATLAS ACS TIMI 46 Rivaroxaban Comparator Odds Ratio M-H, Random Events Total Events Total Weight (95% CI) % 0.83 ( ) % 0.75 ( ) Odds Ratio M-H, Random, 95%CI RECORD % 1.18 ( ) RECORD % 1.34 ( ) RECORD % 0.51 ( ) RECORD % 0.20 ( ) ROCKET AF % 0.80 ( Total % 0.82 ( ) Total events Heterogeneity: Tau²=0.00; Chi²=2.93; df=6 (p=0.82; I²=0% Test for overall effect: Z=3.05 (p=0.02) Rivaroxaban better Comparator better Chatterjee S et al. presented at AHA
15 Question to the audience: What would be the recommended dose of Rivaroxaban for our patient? 1 2 x 15mg 2 1 x 15mg 2 1 x 20mg 3 2 x 2.5mg Dosing of new oral anticoagulants for stroke prevention in atrial fibrillation Anticoagulant Dabigatran etexilate Rivaroxaban Apixaban Dosing for stroke prevention in atrial fibrillation 2x150mg >80years or with high bleeding risk: 2x110mg CrCl and high bleeding risk: 2x110mg CrCl <30: contraindication 1x20mg CrCl 15 49: 1x15mg CrCl <15: contraindication 2x5mg CrCl 15-49: 2x2.5mg CrCl <15: contraindication 15
16 Adherent patients (%) Bleeding incidence (%) Adherent patients (%) Ratio (edoxaban/warfarin) 1/19/2015 od drugs within a polydrug regimen show better adherence than bid drugs 10,697 patients with AF initiated on diabetes and hypertension drugs: 45% already taking 2 different drugs at baseline (US: ) Overall adherence # MPR 0.8 * Total population *p<0.001 vs bid; # Mean exposure: 447 days od, 406 days bid; p=0.017 vs bid Laliberté et al, Adv Ther 2012;29: Age 65 years * Adherent patients over time PDC 0.8 * od bid Months since therapy initiation * * Edoxaban phase II data support the selection of od dosing in AF: higher bleeding rates in bid correlated with higher C trough Total daily dose 30 mg Total daily dose 60 mg Total daily dose 120 mg * * /235 19/234 32/244 34/180 22/250 Edoxaban 30 mg od Edoxaban 60 mg od Edoxaban 30 mg bid Edoxaban 60 mg bid Warfarin N=1146 patients with AF *p<0.03 vs warfarin 1. Salazar et al. Thromb Haemost 2012;107: ; 2. Weitz et al. Thromb Haemost 2010;104:
17 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Question to the audience: How to switch in our case from enoxaparin bid. to Rivaroxaban 1 simultaneous dosing 2 6h after last dose of enoxaparin 2 12h after last dose of enoxaparin 3 24h after last dose of enoxaparin 17
18 Anti-Factor Xa activity (change from baseline; ng/ml enoxaparin) 1/19/2015 New anticoagulants: Switching strategies VKA to NOAC Parenteral anticoagulant to NOAC: Intravenous unfractioned heparin (UFH) Low molecular weight heparin (LMWH) INR <2.0: immediate INR : immediate or next day INR >2.5: use INR and VKA half-life to estimate time to INR <2.5 Start once UFH discontinued (t½=2h). May be longer in patients with renal impairment Start when next dose would have been given NOAC to VKA Administer concomitantly until INR in appropriate range Measure INR just before next intake of NOAC Re-test 24h after last dose of NOAC Monitor INR in first month until stable values ( ) achieved NOAC to parenteral anticoagulant NOAC to NOAC Initiate when next dose of NOAC is due Initiate when next dose is due except where higher plasma concentrations expected (e.g. renal impairment) Aspirin or clodiprogel to NOAC Switch immediately, unless combination therapy needed Heidbuchl et al. EP Europace 15: (2013) Evidence for od dosing: similar onset of action to enoxaparin 4 Enoxaparin 40 mg Rivaroxaban 10 mg Time (hours) Note: This was one of the early observations that suggested that od might be feasible Kubitza et al. J Thromb Haemost 2005;3(Suppl.1):P
19 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Case 3 A 48-year-old man has been treated for 2 months with warfarin for AF No bleeding problems; INR regulation is average General health is excellent He will be travelling in rural India for the next 4 months with little access to medical facilities and only intermittent facilities for international communication 19
20 Question to the audience: How should Rivaroxaban treatment be monitored? 1 INR should be tested every month 2 PTT should be tested every month 2 anti-xa should be tested every month 3 None of the above Measuring NOACs - If you seek to measure drug activity in cases of overdosing or bleeding: - Anti Xa chromogenic assay for Rivaroxaban - Anti IIa chromogenic assay or dtt for Dabigatran - In our experience rarely necessary - INR, PTT, and other coagulation tests will be altered but are not clinically meaningful 20
21 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Case 4 A 60-year-old man taking Rivaroxaban 1x20mg/d for AF since 2 months Presents in the ER with acute symptomatic gastric bleeding Drop in Hemoglobin by 5 points 21
22 ESC Guidelines 2012 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach 22
23 Case 6 77-year-old female with AF, treated rivaroxaban 1x20 mg/d Must undergo urgent cholecystectomy No prior bleeding problems; New anticoagulants: elective surgery Before surgery After surgery Dabigatran CrCl>80: 24h (high risk 2d) 50-80: 1-2d (high risk 2-3d) 30-50: 2-3d (high risk 4d) as soon as possible Rivaroxaban at least 24h as soon as possible 23
24 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Case 7 82-y/o female with posterior MI CVRF: Hypertension, Diabetes ND: chron. OAC with Warfarin for Afib Cath: 2-VD, Occlusion RCA, medial 90% LAD-Stenosis Th.: PCI/DES RCA acutely and PCI/DES LAD Seite 49 24
25 Patents with ACS and DE-Stent The Freiburg Regimen PPI ASS Clopidogrel VKA INR 2,0-2,5 INR Month 1 Year ACS/ DE-Stent Eur Heart J Jan;35(4): Patents with ACS and DE-Stent The Freiburg Regimen PPI ASS Clopidogrel Riva 10mg Riva 15mg Riva 20mg 1 Month 1 Year ACS/ DE-Stent 25
26 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach EHRA practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation Hein Heidbuchel 1, M.D., Ph.D., Peter Verhamme 1, M.D., Ph.D., Marco Alings 2, M.D., Ph.D., Matthias Antz 3, M.D., Werner Hacke 4, M.D., Jonas Oldgren 5, M.D., Ph.D., Peter Sinnaeve 1, M.D., Ph.D., A. John Camm 6, M.D., Paulus Kirchhof 7, M.D., Ph.D. 1. Department of Cardiovascular Medicine, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium; 2. Department of Cardiology, Amphia Ziekenhuis, Breda, Netherlands; 3. Department of Cardiology, Klinikum Oldenburg, Oldenburg, Germany; 4. Department of Neurology, Ruprecht Karls Universität, Heidelberg, Germany; 5. Uppsala Clinical Research Center and Dept of Medical Sciences, Uppsala University, Uppsala, Sweden; 6. Clinical Cardiology, St George s University, London, United Kingdom; 7. University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK, and Department of Cardiology and Angiology, University of Münster, Germany 26
27 New anticoagulants: Practical issues to be discussed Background, Pharmacology, and Platform of evidence for NOACs ESC Guideline Update 2012 Case Presentations Practical Issues to be discussed Dosing Switching Monitoring vs. Measuring Bleeding Elective Surgery Triple Therapy (DAPT+OAC) EHRA Guide Ongoing Studies Conclusion: Individualized therapeutic approach Take home messages: NOACs are superior to Warfarin in terms of efficacy and safety. Direct comparison between the trials and particularly between subgroups is unsound given the differences in design and collective. The question which drug for which patient should be based on trial data and basic pharmacology. Factor Xa inhibitors such as rivaroxaban are more suited for the elderly and renally impaired than DTIs. Rivaroxaban affords the added advantage of a single dosing, broad spectrum of indications, and excellent data in CV comorbidity. 27
28 What is the bleeding risk under triple therapy? Paikin et al. Circulation 2010;121;
29 Cumulative incidence of bleeding 1/19/2015 Consensus Statement triple therapy 2010 Thromb Haemost 2010; 103: The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting 50 % 40 % 30 % 20 % 10 % 0 % Days n at risk:
30 WOEST p= Secondary Endpoint p= Lancet 2013:381: Double therapy group 6 5 p= Triple therapy group p= p= Death MI TVR Stroke ST MI=any myocardial infarction; TVR= target vessel revascularisation (PCI + CABG); ST= stent thrombosis 30
31 XARELTO (rivaroxaban) Use in Patients With AF Undergoing PCI: PIONEER AF-PCI 2100 patients with NVAF No prior stroke/tia PCI with stent placement 72 hours After Sheath removal R A N D O M I Z E 1,6, or 12 months XARELTO 2.5 mg bid Clopidogrel 75 mg qd Aspirin mg qd 1,6, or 12 months VKA (target INR ) Clopidogrel 75 mg qd Aspirin mg qd XARELTO 15 mg qd* Clopidogrel 75 mg qd XARELTO 15mg QD Aspirin mg qd VKA (target INR ) Aspirin mg qd End of treatment at 12 months Primary endpoint: TIMI major, minor, and bleeding requiring medical attention Secondary endpoint: CV death, MI, stroke, and stent thrombosis *10 mg od in patients with CrCl of 30 to <50 ml/min. Alternatively: 10 mg prasugrel od or 90 mg ticagrelor bid. Data on File. Janssen Pharmaceuticals, Inc. 31
Breadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationRivaroxaban. Practical Experience in the Cardiology Setting. Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationAdherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationNOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology
NOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology Department of Medicine Division of Cardiology Nykøbing F Hospital Denmark Disclosure of Conflict of Interest
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationTriple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationInvestor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationThe importance of adherence and persistence: The advantages of once-daily dosing
The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationFinancial Disclosures
Financial Disclosures Consulting: AstraZeneca, Bayer, Boehringer Ingleheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Ortho/McNeill, Pfizer,
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationDirect oral anticoagulants in daily care: what do we know today and what are the remaining issues?
De afbeelding kan niet worden weergegeven. Mogelijk is er onvoldoende geheugen beschikbaar om de afbeelding te openen of is de afbeelding beschadigd. Start de computer opnieuw op en open het bestand opnieuw.
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationAuthors: Partha Sardar MDa; Saurav Chatterjee MDb; Joydeep Ghosh MDc; Debabrata Mukherjee MD, MS d, Gregory Y H Lip MD, FRCP, FACC, FESCe.
Risk of Major Bleeding in Different Indications for New Oral Anticoagulants: Insights from a Meta- Analysis of Approved Dosages from 48 Randomized Trials Authors: Partha Sardar MDa; Saurav Chatterjee MDb;
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationCurrent Controversies in Management of Anticoagulation for Atrial Fibrillation
Current Controversies in Management of Anticoagulation for Atrial Fibrillation Cheri Silverstein Fadlon, MD MSCR Assistant Professor of Internal Medicine, COMP Cardiologist, Western Diabetes Institute
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationStroke prevention in AF: Insights from Clinical Trials and Real Life Experience
Stroke prevention in AF: Insights from Clinical Trials and Real Life Experience A. John Camm St. George s University of London and Imperial College London, UK Approval Number G.MA.GM.XA.10.2015.0723 Disclosure
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationMEETING THE CHALLENGES IN ATRIAL FIBRILLATION MANAGEMENT: THE ROLE OF NEW ANTICOAGULANTS
MEETING THE CHALLENGES IN ATRIAL FIBRILLATION MANAGEMENT: THE ROLE OF NEW ANTICOAGULANTS Summary of Presentations from the Daiichi Sankyo Satellite Symposium, held at the Annual ESC Congress, Barcelona,
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationHow to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationxaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationCapri Cardiovascular Conference 2.0 Capri, 28-29 marzo 2014
Capri Cardiovascular Conference 2.0 Capri, 28-29 marzo 2014 Web Round Table Rivaroxaban nella fibrillazione atriale e oltre 29 marzo 2014 - ore 9:30-10:45 Rivaroxaban ed il valore della monosomministrazione
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More information